Alberto A Chiappori

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations
    Andrew Kuykendall
    Thoracic Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 21:67-73. 2014
  2. pmc Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
    Claudia Marcela Diaz
    Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
    J Transl Med 11:62. 2013
  3. pmc A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
    A A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Br J Cancer 106:839-45. 2012
  4. pmc INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
    Alberto A Chiappori
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Expert Opin Biol Ther 10:983-91. 2010
  5. pmc Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:484-90. 2010
  6. doi request reprint Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Thorac Oncol 5:369-75. 2010
  7. ncbi request reprint Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 14:1464-9. 2008
  8. ncbi request reprint A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer
    Alberto A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Thorac Oncol 1:1010-9. 2006
  9. ncbi request reprint Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
    Jade Homsi
    H Lee Moffitt Cancer Center, Tampa, Florida 33612 9497, USA
    Clin Cancer Res 13:5855-61. 2007
  10. ncbi request reprint A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors
    Alberto A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 13:2091-9. 2007

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations
    Andrew Kuykendall
    Thoracic Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 21:67-73. 2014
    ..Molecular targets, such as epidermal growth factor receptor (EGFR), involved in cell signaling have led to the development of new, targeted therapies over the past 15 years...
  2. pmc Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
    Claudia Marcela Diaz
    Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
    J Transl Med 11:62. 2013
    ..We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV disease...
  3. pmc A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
    A A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Br J Cancer 106:839-45. 2012
    ..Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy...
  4. pmc INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
    Alberto A Chiappori
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Expert Opin Biol Ther 10:983-91. 2010
    ..p53 gene mutations often occur, resulting in tumoral protein overexpression and allowing for their recognition by p53-specific cytotoxic T cells...
  5. pmc Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:484-90. 2010
    ..Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC...
  6. doi request reprint Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Thorac Oncol 5:369-75. 2010
    ..We examined the efficacy of enzastaurin plus pemetrexed as second-line therapy in patients with advanced (stage IIIA/B or IV) non-small cell lung cancer in a double-blinded, randomized, phase II study...
  7. ncbi request reprint Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 14:1464-9. 2008
    ..This study was designed to assess the influence of atrasentan on paclitaxel pharmacokinetics and to determine the safety and efficacy of atrasentan in combination with paclitaxel-carboplatin...
  8. ncbi request reprint A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer
    Alberto A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Thorac Oncol 1:1010-9. 2006
    ..Erb-B family receptor elevations are found in many non-small cell lung cancer tumors, making this receptor family a drug target with potential for improving survival...
  9. ncbi request reprint Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
    Jade Homsi
    H Lee Moffitt Cancer Center, Tampa, Florida 33612 9497, USA
    Clin Cancer Res 13:5855-61. 2007
    ..We studied a weekly schedule of CT-2106 in patients with refractory solid tumor malignancies...
  10. ncbi request reprint A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors
    Alberto A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 13:2091-9. 2007
    ..S-3304 is a potent, orally active, noncytotoxic inhibitor of MMPs, primarily MMP-2 and MMP-9, that prolongs survival in mice xenografts and is well tolerated in healthy volunteers...
  11. ncbi request reprint Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer
    Richard D Hall
    Hematology Oncology Fellowship Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 20:22-31. 2013
    ..New approaches are needed to improve overall survival beyond the current standard of care...
  12. doi request reprint Increased cyclin D3 expression significantly correlates with p27 nuclear positivity in gastrointestinal stromal tumors
    Nicole Draper
    Department of Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Hum Pathol 39:1784-91. 2008
    ..We report a direct correlation between cyclin D3 and p27 expression in gastrointestinal stromal tumors. Additional alterations in cyclin D1, Ki-67, and retinoblastoma protein expression indicate a disregulated cell cycle in these tumors...
  13. ncbi request reprint Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
    Mayer N Fishman
    Experimental Therapeutics and Phase I Programs, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Clin Cancer Res 12:523-8. 2006
    ..It has superior activity in experimental tumor models when compared with paclitaxel. BMS-188797 has a single C-4 modification, a 4-desacetyl-4-methylcarbonate, compared with paclitaxel...
  14. ncbi request reprint Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer
    Tawee Tanvetyanon
    Thoracic Oncology Program, Moffitt Cancer Center, Tampa FL 33612, USA
    Cancer Control 21:32-9. 2014
    ..In the management of non-small-cell lung cancer (NSCLC), genomic and proteomic profiling applications have become useful in early disease detection, diagnosis, treatment, and prognostication...
  15. pmc Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings
    Virendra Kumar
    Department of Imaging, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9416, USA
    Clin Nucl Med 38:175-82. 2013
    ..In this study, we measured test-retest reproducibility of SUV measurements under clinical practice conditions and recorded recognized deviations from protocol compliance...
  16. ncbi request reprint Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 25:3936-44. 2007
    ..To evaluate the efficacy of the pan-ERBB inhibitor, CI-1033, in platinum-refractory or recurrent advanced-stage non-small-cell lung cancer (NSCLC)...